Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Upstream Bio, Inc. (UPB : NSDQ)
 
 • Company Description   
Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio Inc. is based in WALTHAM, Mass.

Number of Employees: 52

 
 • Price / Volume Information   
Yesterday's Closing Price: $11.84 Daily Weekly Monthly
20 Day Moving Average: 478,513 shares
Shares Outstanding: 53.79 (millions)
Market Capitalization: $636.92 (millions)
Beta:
52 Week High: $29.46
52 Week Low: $5.14
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.42% -1.41%
12 Week 34.85% 13.43%
Year To Date -27.98% -32.55%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
890 Winter Street Suite 200
-
Waltham,MA 02451
USA		 ph: 781-208-2466
fax: -		 ir@upstreambio.com http://www.upstreambio.com
 
 • General Corporate Information   
Officers
E. Rand Sutherland - Chief Executive Officer and Director
Ronald C. Renaud, Jr. - Chairman
Michael Paul Gray - Chief Financial and Operating Officer
Daniella Beckman - Director
Erez Chimovits - Director

Peer Information
Upstream Bio, Inc. (CORR.)
Upstream Bio, Inc. (RSPI)
Upstream Bio, Inc. (CGXP)
Upstream Bio, Inc. (BGEN)
Upstream Bio, Inc. (GTBP)
Upstream Bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 91678A107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 53.79
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $636.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.57 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.43
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -11.56%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - 47.43
12/31/24 - 44.63
Quick Ratio
06/30/25 - -
03/31/25 - 47.43
12/31/24 - 44.63
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -2,650.04
Book Value
06/30/25 - -
03/31/25 - 8.30
12/31/24 - 8.77
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©